

ICHOR LIFE SCIENCES™


Certificate of Analysis (CoA) – Finnrick Analytics

Test Article:	Tirzepatide	Report Date:	21-Sep-2026
Finnrick Record ID:	byqhqfb	Date Tested:	13-Sep-2026
Label Claim:	30mg	Date Received:	03-Sep-2026
CAS No:	2023788-19-2		
Storage:	-20°C		
Appearance:	White to off-white powder		

Results:

Target Molecular Mass:	4813 Da
Target Known Fragment Masses (Da):	396, 980, 2209
Sample Observed Fragment Masses (Da):	396, 980, 2209
Identity Confirmation:	Confirmed Tirzepatide
Purity (HPLC-UV):	100
Net Peptide Content (mg):	29.11


Images:




HPLC Method:

Column	Xbridge Peptide BEH C18, 300 angstrom, 5µm, 4.6 mm x 150 mm	
Mobile Phase A	Water + 0.1% Trifluoroacetic Acid	
Mobile Phase B	Acetonitrile + 0.1% Trifluoroacetic Acid	
Flow Rate	1 mL/min	
Column Temperature	25°C	
Injection volume	10 µL	
Wavelength	215 nm	
Gradient Flow Details		
Time (min)	% Mobile Phase A	% Mobile Phase B
0	80	20
1	80	20
20	40	60
25	10	90
25.1	80	20
30	80	20

Mass Spectrometry Standard:



HPLC Results:



Ichor Life Sciences, Inc.

831 James Street, Syracuse, NY 13203

Phone: 315.677.8400

info@ichorlifesciences.com | www.ichorlifesciences.com

Peak Results					
	Name	RT	Area	Height	% Area
1	Tirzepatide	19.304	8240205	896984	100.00

Methodology:


Identity Criteria:	Peptide samples were analyzed by direct infusion under positive electrospray ionization conditions. The neutral monoisotopic mass was calculated or generated through spectral deconvolution and compared with the theoretical monoisotopic mass calculated from the peptide sequence.
Purity Basis:	1 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder. An aliquot is taken from the vial and diluted to contain 1 gram per liter of the peptide. The diluted sample is then used for HPLC-UV analysis. The total area of all peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the chromatographic purity value, reported in percent. The area of the peptide is compared to the area of the peptide peak in a known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

The analytical methods used here have not been evaluated or approved by the FDA. The results should be considered "For Research Use Only" and not used for diagnosis, treatment, prevention, monitoring or alleviation of a disease, injury or disability; and the results are not intended to be medical advice. The results have not been subjected to any conformity assessment or other regulatory review, or certified, approved, or cleared by any conformity assessment body or other regulatory body in any country for diagnostic use or any other purpose.

Approved by: Scott Campbell

Title: Research Associate II

Signature:



SAFER.